METHODS OF TREATING INFERTILITY
    33.
    发明申请
    METHODS OF TREATING INFERTILITY 有权
    治疗感染的方法

    公开(公告)号:US20160250296A1

    公开(公告)日:2016-09-01

    申请号:US15053116

    申请日:2016-02-25

    申请人: FERRING B.V.

    摘要: The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.

    摘要翻译: 本发明涉及使用高度纯化的促黄体素(HP-hMG)在受控的卵巢刺激中刺激卵泡发育的改善的辅助生殖技术,特别是在受控卵巢刺激的卵巢反应高的妇女中。

    OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES
    35.
    发明申请
    OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES 有权
    氧化铁受体拮抗剂治疗在辅助生殖技术领域的妇女植入和孕育的阶段

    公开(公告)号:US20160175283A1

    公开(公告)日:2016-06-23

    申请号:US14643307

    申请日:2015-03-10

    申请人: Ferring B.V.

    发明人: Joan-Carles Arce

    IPC分类号: A61K31/404 A61B17/435

    摘要: The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.

    摘要翻译: 本发明涉及催产素受体拮抗剂在经历胚胎移植的雌性中作为辅助生殖技术的一部分的用途。 特别地,提供了用于在接受胚胎移植的女性受试者中增加持续的植入率,增加持续怀孕率,增加临床怀孕率和/或增加活产率的方法。 具体地,当子宫内膜接受胚胎植入和/或当胚胎达到囊胚期时,拮抗剂在黄体期释放。

    STABILIZATION OF FSH
    38.
    发明申请
    STABILIZATION OF FSH 有权
    FSH的稳定性

    公开(公告)号:US20150265681A1

    公开(公告)日:2015-09-24

    申请号:US14631382

    申请日:2015-02-25

    申请人: Ferring B.V.

    摘要: The present invention pertains in general to the field of stabilization of FSH formulations, in particular liquid FSH formulations. The stabilization is achieved by the addition of salts comprising pharmaceutically acceptable alkali metal cations, in preferred embodiments by the addition of pharmaceutically acceptable salts, i.e. sodium salts or potassium salts.

    摘要翻译: 本发明一般涉及FSH制剂,特别是液体FSH制剂的稳定化领域。 通过加入包含药学上可接受的碱金属阳离子的盐来实现稳定化,在优选的实施方案中通过加入药学上可接受的盐即钠盐或钾盐来实现。

    Misoprostol Composition
    39.
    发明申请
    Misoprostol Composition 审中-公开
    米索前列醇组合物

    公开(公告)号:US20150174139A1

    公开(公告)日:2015-06-25

    申请号:US14415957

    申请日:2013-07-25

    申请人: Ferring B.V.

    摘要: The present invention relates to the use of misoprostol for the induction of labour in a pregnant female, and in particular to the use of a sustained delivery device or insert containing substantially 200 μg misoprostol for intravaginal use. The use encompasses methods of therapy as well as compositions for use in such methods.

    摘要翻译: 本发明涉及使用米索前列醇用于在怀孕女性中诱导劳动,特别是使用含有基本上200μg米索前列醇用于阴道内使用的持续递送装置或插入物。 该用途包括治疗方法以及用于这些方法的组合物。

    Hydrophilic Polyurethane Compositions
    40.
    发明申请
    Hydrophilic Polyurethane Compositions 审中-公开
    亲水性聚氨酯组合物

    公开(公告)号:US20150165044A1

    公开(公告)日:2015-06-18

    申请号:US14616314

    申请日:2015-02-06

    申请人: Ferring B.V.

    摘要: This disclosure relates to a controlled-release composition containing a water-swellable linear polymer together with an active agent. The water-swellable linear polymer is obtained by reacting together: (a) a polyethylene oxide of number average molecular weight less than or equal to 4000 g/mol; (b) an aliphatic diol; and (c) a difunctional isocyanate. The ratio of components (a) to (b) to (c) is in the range of 0.01-0.1 to 1 to 1.01-1.1 in terms of equivalent weights. The amount of the polyethylene oxide is less than 50 wt % of the polymer. The polymer has a water swelling percentage of 20-100%.

    摘要翻译: 本公开涉及含有水溶胀性线性聚合物与活性剂的控释组合物。 水溶胀性线性聚合物通过以下反应获得:(a)数均分子量小于或等于4000g / mol的聚环氧乙烷; (b)脂肪族二醇; 和(c)双官能异氰酸酯。 组分(a)至(b)至(c)的比例以当量重量计在0.01-0.1至1至1.01-1.1的范围内。 聚环氧乙烷的量小于聚合物的50重量%。 聚合物的水溶胀百分比为20-100%。